Cyclerion Therapeutics, Inc. CYCN

Cyclerion Therapeutics Inc. has reported significant financial losses for the quarter ending May 14, 2026, with a net loss of $5.28 million and earnings per share of -$1.37, leading to a steep decline in stock value. This follows increased scrutiny regarding its all-stock merger with Korsana Biosciences, which had previously seen Cyclerion's shares rise dramatically after the announcement. Currently, concerns over market valuation and shareholder interests persist as Cyclerion's stock trades around $3.15, raising alarms about its financial stability and deal terms with Korsana amid ongoing investigations.